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Abstract Complete surgical resection beyond tumor
margins cannot be achieved in glioblastoma multiforme
(GBM) because of infiltrative nature. In several cancers,
neoadjuvant treatment has been implemented to reduce the
risk of tumor cell spreading during resection. In GBM, the
objective of a neoadjuvant approach is reduction of tumor
cells within the main tumor mass and beyond in the infil-
tration zone. Such an approach can only be performed if
elevated intracranial pressure can be medically controlled. In
a previous study with recurrent gliomas, we showed that
local intratumoral injection of radiolabeled DOTAGA–
substance P substantially inhibited further growth and led to
radionecrotic transformation of the tumor (CCR 2006). We
have now examined this modality as neoadjuvant treatment
for GBM, primarily assessing feasibility, toxicity, the extent
of resection, and functional outcome. After diagnosis of
GBM, 17 patients were included in a prospective phase I
study. Repetitive intratumoral injections of radiolabeled
DOTAGA–substance P were performed, followed by sur-
gical resection. Chemical synthesis, radiolabeling, and local
injection of the peptidic vector [90Yttrium]-DOTAGA–
substance P were described previously. Neoadjuvant injec-
tion of [90Y]-DOTAGA–substance P was feasible without
decompensation of intracranial pressure. Prolonged appli-
cation of corticosteroids was identified as the main risk factor
for side effects. Fifteen patients stabilized or improved their
functional status. The mean extent of resection in subsequent
surgery was 96%. Neoadjuvant therapy of GBM using
locally injected radiolabeled DOTAGA–substance P was
feasible and of low toxicity. The high extent of resection and
concomitant irradiation of tumor cells in the infiltration zone
may be prognostically relevant.
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Purpose
Malignant gliomas continue to be a therapeutic challenge
because the prognosis of gliomas has not significantly
improved over recent decades [1]. Median survival in highly
proliferative glioblastoma multiforme (GBM) ranges from
10 to 18 months [2–4]. Currently, surgical resection fol-
lowed by a combination of external beam radiotherapy and
chemotherapy [2] is generally accepted as the standard of
care for GBM. However, other groups discuss a less
aggressive strategy. Ostertag et al. [5] did not find a sig-
nificant difference in the survival of GBM patients (RTOG
classes IV–VI) when treated by surgery and subsequent
radiotherapy as compared with biopsy only and subsequent
radiotherapy, if there was no significant mass effect.
An essential feature of malignant gliomas is that 95% of
these tumors are unifocal lesions that exhibit local recur-
rence [6]. The extent of resection in malignant gliomas is
widely accepted to positively correlate with time to the
recurrence of the tumor [7–9], which underscores the
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importance of a sufficient local control of the tumor.
Currently, several regimens of targeted loco-regional
therapy are in development to improve local tumor control.
These therapeutic systems are usually locally administered
bifunctional molecules that consist of a targeting domain,
for example the interleukin-4 or 13 receptors [10, 11] or
monoclonal antibodies against tenascin-C [12], and of an
effector domain, for example bacterial toxins [13] or
radioisotopes [14]. Toxin-delivering conjugates have to
target every single tumor cell, whereas radionuclide-based
approaches also target receptor-negative tumor cells by the
range-dependant crossfire effect [15].
In a previous study we have shown the feasibility and low
toxicity of targeting recurrent malignant gliomas with
radiolabeled substance P as a second-line treatment [16].
Substance P is the physiological ligand of the transmemb-
raneous neurokinin type 1-receptor (NK1-R) which is con-
sistently overexpressed in malignant gliomas of WHO grade
II-IV. NK1-receptors have also been detected on tumor cells
infiltrating the intratumoral and peritumoral vasculature
[17]. The radiolabeled pharmaceutical 1,4,7,10-tetra-
azacyclododecane-1-glutaric acid-4,7,10-triacetic acid–
substance P (DOTAGA–substance P) has a preserved
affinity for the NK-1 receptor in the low nanomolar range.
The vector has a low molecular weight of only 1.8 kDa,
which is a prerequisite for sufficient and rapid intratumoral
distribution following local injection, especially in the
critical infiltration zone of the tumor. The targeted second-
line treatment as described in our previous study [16] led to a
good functional outcome and may also improve survival
times. Furthermore, we found tumor resection to be signif-
icantly facilitated by better demarcation of the tumor. The
fact that tumor vessels also are targeted by this therapy adds
another important mode of action, because antiangiogenic
therapeutic approaches have repeatedly been shown to
exhibit positive therapeutic potential [18–20].
Neoadjuvant therapy is a well-established treatment
strategy in different types of cancer, for example neoad-
juvant chemoradiation followed by surgery and adjuvant
chemotherapy is widely accepted in the treatment of
colorectal cancer patients with locally advanced tumors
[21, 22]. Different neoadjuvant approaches have also been
introduced for the treatment of breast cancer [23, 24].
Improved local control of the tumor and treatment of sys-
temic tumor burden are regarded as the main mechanisms
responsible for the positive impact of neoadjuvant therapy.
High-grade gliomas as brain-intrinsic neoplasms differ
from other malignancies in several aspects:
1 The location of the tumor in a closed cavity carries the risk
of a symptomatic increase of the intracranial pressure
because of further tumor growth or peritumoral edema.
2 The surgical principle to perform the resection beyond a
safety margin cannot be applied to this highly infiltrative
type of tumor which often involves functionally impor-
tant areas of the brain. In addition, glioma cells
infiltrating the surrounding brain tissue cannot be
reliably detected by contemporary imaging studies.
3 Systemically administered chemotherapy reaches the
cerebral compartment only to a limited extent, because
of the blood–brain barrier. Reduced intratumoral drug
concentration because of the blood–brain barrier and
inherent chemoresistance lead to limited efficacy [25].
4 Hypoxia and an acidotic milieu of the intratumoral and
peritumoral microenvironment reduce the efficacy of
radiation and chemotherapy. Elevated interstitial fluid
pressure induces a heterogeneous blood flow, leading to
highly variable distribution of systemically adminis-
tered drugs and represents an additional barrier against
an efficient drug distribution [26].
In this paper we present the results of 17 GBM patients
who were treated with radiolabeled substance P as the
primary therapeutic modality followed by surgical resec-
tion. The main idea behind the local targeted neoadjuvant
therapy with radiolabeled substance P is to optimize the
achievable extent of resection and reduction of the
spreading of tumor cells during resection. An additional
factor may be the targeting of tumor cells in the infiltration
zone. Primary endpoints of the study are the feasibility and
toxicity of this approach. Secondary endpoints are the
extent of resection assessed by comparison of preoperative
tumor volumes and postoperative residual tumor volumes.
The functional outcome of the patients was assessed by use
of the Barthel index.
Patients and methods
Patients
The clinical data of the study patients are summarized in
Table 1. The study protocol as displayed in Fig. 1 was
approved by the Ethics Committee of the University Hos-
pitals of Basel. Patients were evaluated weekly for the first
two months and thereafter according to the course of the
disease. Functional status was assessed by use of the Bar-
thel index [27]. Before inclusion, informed consent was
obtained.
Inclusion criteria
Newly diagnosed and histopathologically confirmed GBM,
maximal tumor diameter 7 cm, unifocal lesion, no evi-
dence for obstruction of CSF circulation or decompensat-
ing intracranial pressure, Karnofsky performance score of
50 or higher, age 18–75 years, informed consent.
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Exclusion criteria
Previous treatment of the glioma, low-grade glioma or
anaplastic glioma, concurrent malignant neoplastic disease,
inability to give informed consent.
Study protocol
Week 1
Stereotactic biopsy, intratumoral implantation of 1–3
catheter systems in case of confirmation of GBM in a fresh
frozen section. Catheter systems (Fig. 2) were stereotacti-
cally placed within the tumor margins, usually at the site of
assumed prognostically relevant further tumor spread. The
number of implanted catheter systems depended on the size
and configuration of the tumor. Local test injection for
confirmation of positive expression of binding sites and
evaluation of intratumoral dose distribution was performed
with [111Indium]-DOTAGA–substance P.
Weeks 2–5
Intratumoral injection of [90Y]-DOTAGA–substance P at
weekly intervals. Cumulative injected activities were in the
range between 120 mCi and 345 mCi with an increase of
the dose in the course of the study (dose escalation). Cor-
ticosteroid medication was administered throughout the
pre-OP treatment protocol.
Week 7
Surgical resection of the tumor. MRI scan within 72 h for
assessment of the extent of resection.
Follow up
MRI scan every six weeks; clinical evaluation every
4–6 weeks after resection of the tumor; clinical evaluation
weekly during application of radiopeptides.
Table 1 Patients included in the study
Patient
no.
Age at
diagnosis
(years), sex
GBM
location
Cycles/
cumulative
dose (mCi)
Extent of
resection
(%)
Barthel
index d
(pre/post)
Post-op.
adjuvant
therapy
Progression
free survival
(months)
Overall
survival
(months)
GBM study patients
1 43, m t, L 4/120 90 100/100 SP, RT, CH 9 18
2 69, m f, L 4/120 90b 80/70 SP 7 10
3 61, f p, L 4/120 c 50/60 r/s c 15
4 66, f f, L 2a/100 95 90/100 RT, CH 5 16
5 59, f po, L 3/170 97 100/100 SP, CH 7 10
6 74, f f, L 3/180 99 80/80 s 6 8
7 64, m po, L 4/210 98 100/100 SP 8 10e
8 63, m t, R 4/240 100 85/100 SP 21 23
9 50, f po, R 4/240 98 100/100 SP 12 19
10 54, f f, L 4/345 100 75/90 SP, CH 8 13
11 55, m po, R 4/120 c 90/90 r/s c 6
12 60, m po, L 0a/– 100 100/100 RT, CH 23? 23?
13 34, f ft, R 2/140 98 100/100 RT, CH 5 18?
14 32, f p, R 1/100 97 100/100 RT, CH 17? 17?
15 67, m t, L 1/100 95 100/100 RT, CH 11? 11?
16 60, m t, L 2/240 100 80/80 RT, CH 9? 9?
17 54, m t, L 2/240 89 80/90 RT, CH 7? 7?
f, frontal; t, temporal; po, parieto-occipital; L, left; R, right; SP, intracavitary radiolabeled substance P; RT, external beam radiotherapy;
CH, temozolomide chemotherapy; r, refusal; s, supportive care
a Obstruction of catheter system
b No complete resection intended
c Refusal of follow-up and imaging studies
d Examination at diagnosis and after neoadjuvant radiopeptide therapy
e Death due to intracerebral hemorrhage
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Postoperative treatment
According to the patient’s wish, continuation of radio-
peptide therapy after the resection or standard treatment
with external beam radiotherapy and/or chemotherapy.
Approved amendment of the treatment protocol after 12
patients: Shortening of the protocol from four preoperative
injections to only one or two injections with a minimum
injected dose of 100 mCi preoperatively.
Radioconjugates
For the synthesis, radiolabeling, and preparation of the
peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric
acid-4,7,10-triacetic acid-substance P see Kneifel et al.
[16].
Injection of the radiopharmaceutical [28–30]
Preparation of the patient with 12 mg dexamethasone and,
immediately before injection, 60 g of the osmodiuretic
drug mannitol for transient reduction of the intratumoral
pressure. Before injection of the active compound, the
system is flushed with 1.5 ml 5% human albumin to coat
the plastic surface. Thereafter the active drug is injected in
a volume of 0.5–1.5 ml. Finally, the system is flushed
again with 1.5 ml 5% human albumin. Usually patients
stayed in the hospital for the day of injection and the
subsequent day.
Evaluation of binding sites and dose distribution [31]
Each patient was injected with 1 MBq [111Indium]-
DOTAGA–substance P as a test injection before the first
therapeutic cycle. The biodistribution was followed by
SPECT/CT performed 0, 6, 24, and 30 h after injection.
Therapeutic activity was administered only if a localized
orthotopic dose distribution within the tumor could be
observed, i.e. no dose deposition outside the tumor margins
visible on CT scan. Images were acquired on a dedicated
SPECT/CT system (SYMBIA T2; Siemens, Malvern, PA,
USA). Four time points were chosen to prove the stable
binding of the radiopharmaceutical within the tumor.
Estimation of the extent of resection
The chosen modality for imaging was magnetic resonance
imaging (MRI); calculation of tumor volumes was per-
formed by using the contrast enhanced T1-sequence. The
tumor area was defined as the area of significant contrast
media enhancement, the perifocal edema was not included
in the calculation. Tumor volumes were calculated by
using the workstation of a commercially available neuro-
navigation system (BrainLab, Germany).
Results
Seventeen patients with GBM were included in this study
as presented above (Table 1). The treatment was well
Brain
Skull
Skin
Intratumoral
Catheter
Tumor
Port
BA
Fig. 2 Intratumoral catheter system. a Schematic drawing of
implanted catheter system. b Catheter system, consisting of a bottom
outlet port capsule and a connected standard intraventricular catheter
Study Protocol
Week 1
Week 2 - 5
Week 7
Stereotactic biopsy and catheter implantation
Test injection with [ 111In]-DOTAGA-SP 
Weekly intratumoral injections
with [90Y]-DOTAGA-SP          
30-90 mCi per injection
Craniotomy and tumor resection
Initial version (Patients 1-12) Amended version (Patients 13-17)
Week 2 (-3) Weekly intratumoral injections
with [90Y]-DOTAGA-SP           
100-150 mCi per injection
Week 3 (or 4) Craniotomy and tumor resection
Fig. 1 Study protocol for
neoadjuvant application of
[90Y]-DOTAGA–substance P
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tolerated by all patients without acute toxicity or side
effects. The preliminary GBM diagnosis from the fresh
frozen sections was confirmed by definite histology in all
cases. Positive NK-1 receptor expression was demonstrated
by the test injection with [111In]-DOTAGA–substance P
(Fig. 3a) in all patients included in the study. The dose
distribution of the test injection was congruent with the
tumor morphology in all cases, with an expected dose
decline towards the tumor periphery. This effect is because
of the three-dimensional spatial distribution of the sub-
stance with a decrease in tissue concentration with
increased distance from the site of injection.
In eight patients four injections were performed in
accordance with the initial study protocol. Patient 4 had
craniotomy and tumor resection after only two injections
because of obstruction of the catheter system, because
implantation of a new catheter system with consecutive test
injection would have added at least one more additional
week to the treatment protocol. In patient 5 and 6 the pro-
tocol was shortened to three preoperative injections only
because of increasing signs of corticosteroid administration
(weight gain). After successful test injection in patient 12,
an obstruction of the catheter system was noted. According
to the patient’s wish in a difficult familial situation, tumor
resection was performed without implantation of a new
catheter and without neoadjuvant pretreatment. In the
remaining five patients, the neoadjuvant treatment protocol
was shortened to only one or two injections with an increase
of the injected dose per treatment cycle for avoidance of
long-term corticosteroid medication.
During the high-dose beta-irradiation performed in this
study, we did not see signs of increasing or decompensating
intracranial pressure in our patients. Another observation dur-
ing surgery of these pretreated tumors was that resectability was
found to be markedly facilitated by pseudoencapsulation of the
tumor accompanied by reduced intraoperative bleeding.
Pseudoencapsulation as observed in this study simply describes
the intraoperative finding that the tumor is surrounded by a
capsule-like structure that can be better dissected from the
surrounding cerebral tissue than in conventional glioma sur-
gery. A non-pretreated malignant glioma intraoperatively
appears as an ill-defined mass. The peripheral zone of tumor
infiltration can often not be distinguished from surrounding
brain parenchyma. Increasing the administered activity
revealed that higher doses lead to a better and more circum-
ferential demarcation of the tumors. Patient 10 received the
highest dose in this series and exhibited complete encapsulation
of the tumor (Fig. 3c). Increasing the doses remained without
relevant side effects possibly attributable to high dose irradia-
tion, as, for example, a critical increase in perifocal edema.
At craniotomy, the extent of tumor resection achieved
was in the range between 90 and 100% (statistical mean
96.6%, SD 3.4) in the 13 patients relevant for evaluation. In
11 out of these 13 patients the extent of resection was at
least 95%. Patient 4 may serve as an illustrative case for the
radiological findings before and after the operation,
including a CT-SPECT-fusion image displaying the dose
distribution at the second therapeutic intratumoral injection
(Fig. 3d–g). Four patients were not included in evaluation
of the extent of resection: patient 2 was not intended for a
Fig. 3 a–c: Patient 10: a Dose distribution as assessed by CT-SPECT
at the pretherapeutic intratumoral test injection. b Contrast-enhanced
postoperative CT-scan. c En bloc removal of the GBM after internal
decompression. Note the capsule-like surface of the resected tumor.
The three catheter systems have been left in situ as anatomical
landmarks. d–g Patient 4: (d, e) Large left frontal GBM in
preoperative T1-weighted and contrast-enhanced MR imaging. (f)
Dose distribution by CT-SPECT at the second therapeutic intratu-
moral injection. (g) T1-weighted and contrast-enhanced MR imaging
after resection of the tumor
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full resection because of his precentral, functionally criti-
cally located tumor; patients 3 and 11 refused any further
diagnostic workup after uneventful surgery because of
severe depression (patient 3) and anosognosia (patient 11).
Patient 12 did not receive the neoadjuvant treatment
because of an obstructed catheter system (see above).
Functional status was evaluated using the Barthel score
[27]. Initial scores were [80 in 10 out of the 16 patients
relevant for evaluation (excluding patient 12), being con-
sistent with no or minor restrictions in everyday-life activi-
ties. After neoadjuvant treatment, nine out of these 10
patients reached a score of 100. The remaining six patients
exhibited scores between 50 and 80. Two of these improved
by 10 points and one by 15; one worsened by 10 points during
neoadjuvant treatment; two remained stable (Table 1).
The postoperative adjuvant treatment of the patients was
adapted to the patients’ wishes and was planned interdis-
ciplinarily (Table 1).
Side effects and adverse events: In the early postoper-
ative phase, patient 16 developed a small dehiscence of the
cranial wound. Local purulent outflow prompted MR
imaging, which was suggestive of an epidural and subdural
abscess. The operative revision confirmed this diagnosis,
the infection was treated with antibiotics according to the
bacterial resistance. In the follow-up six months after
resection of the tumor, patient 8 exhibited a local CSF-
fistula in this late postoperative phase because of a wound-
healing problem. Ten months after diagnosis, patient 7
developed an acute intracerebral hemorrhage adjacent to
the resection cavity within a zone of local tumor recur-
rence. The patient refused further treatment and rapidly
deteriorated. The cause of this hemorrhage could not be
clarified by autopsy which was declined. Most likely, the
hemorrhage originated from local tumor regrowth.
Administration of corticosteroids over the preoperative
neoadjuvant phase led to weight gain in patients 5 and 6.
This prompted patients 5 and 6 to stop further local injec-
tions after three therapeutic cycles and move on to surgery.
No other substantial acute local or systemic toxicity
could be attributed to radiopeptide therapy according to the
NCI CTC toxicity scale (Version 2.0). In the long-term
follow-up, no further relevant local or systemic toxicity
could be found.
Discussion
Although the treatment of malignant gliomas is still con-
troversial, local tumor control is considered to be an
important aspect of treatment. The loco-regional thera-
peutic system developed by our group consists of radiola-
beled substance P, which is a low-molecular-weight
compound of only 1.8 kD. According to our experience,
these small drug-like peptidic vectors rapidly distribute
within the target site and can cross midline structures to
bind to contralateral tumor cells within less than 1 h, as
shown previously [28]. This may be an advantage of small
peptidic vectors in comparison with pharmaceuticals with a
higher molecular weight, e.g. monoclonal antibodies or
immunotoxine conjugates.
By analogy with successful neoadjuvant therapy against
other types of cancer, our objectives are to reduce and
demarcate the main tumor mass and to target tumor cells in
the adjacent area of tumor cell infiltration before surgery.
As a hypothesis, better demarcation should lead to less
tumor cell spread during surgery and a higher extent of
resection. Furthermore, targeting cells in the infiltration
zone of the tumor could carry the potential to prolong the
time to tumor recurrence. Based on our previous experi-
ence with adjuvant radiopeptide therapy, we have set up a
neoadjuvant treatment protocol. This regimen includes
repetitive intratumoral injections with radiolabeled sub-
stance P followed by subsequent resection of the tumor.
Neoadjuvant therapy has so far not been implicated in the
therapeutic algorithm for malignant gliomas, because such
a preoperative procedure always requires a period of time
before definite tumor removal. According to a widely
accepted view among neurosurgeons, a large space-occu-
pying mass ought to be rapidly debulked to reduce
increased intracranial pressure. The need for immediate
aggressive therapy is, however, not generally accepted.
Ostertag et al. [5] did not find a significant difference in the
survival of GBM patients (RTOG classes IV–VI) when
treated by surgery and subsequent radiotherapy compared
with biopsy only and subsequent radiotherapy, if there was
no significant mass effect. For this reason, we did not
include patients with signs and symptoms of decompen-
sating intracranial pressure. Concerning this specific
aspect, in this study we showed that neoadjuvant therapy is
feasible. In the patients treated so far, we did not observe
signs of decompensating intracranial pressure either caused
by further tumor growth or increased perifocal edema
following local high-dose beta-irradiation. To the contrary,
patients often improved after intratumoral radiopeptide
injections. One problem, however, is prolonged depen-
dence on corticosteroids with the risk of secondary Cush-
ing’s syndrome. This risk can potentially be minimized by
reducing the number of treatment cycles and by increasing
the target dose per treatment cycle, as was done in the
course this study. Such intensified treatment algorithms
have been successfully applied in stereotactic radiosurgery.
A rare treatment-related problem in stereotactic radiosur-
gery is late manifestation of cerebral edema, usually after a
few months [32–34]. This delayed phenomenon should not
be relevant in our treatment strategy, because patients are
operated on before reaching the critical time point.
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At the time of resection after neoadjuvant pretreatment,
these diffusely growing tumors were found to be demar-
cated by a pseudocapsular structure. The resection of the
tumors was markedly facilitated, more resembling an
‘‘enucleation’’ after circumferential microsurgical dissec-
tion (Fig. 3c) than conventional glioma surgery. Intraop-
erative bleeding was also found to be markedly reduced,
most probably resulting from the fact that tumor cells
attach to and grow along vascular structures which are
effectively irradiated by the so called crossfire effect of the
beta-particle emitting radionuclides. We expect that these
improvements will lead to a spatially more exact and more
complete removal of the tumor. This is an important aspect,
because a higher extent of resection has been shown to
positively correlate with a prolonged time to recurrence [8]
and possibly overall survival [9]. In this study we observed
a mean extent of resection of 96%, which compares well
with other contemporary techniques with the objective of
optimization of the extent of resection, for example by
using 5-aminolevulinic acid [8] or intraoperative MRI [35,
36]. A substantial advantage of radiopeptide therapy using
small-drug like diffusible vectors may be the additional
targeting of the tumor-infiltrated marginal zone.
Because survival times are very limited in patients with
malignant gliomas, quality of life becomes a fundamental
issue. In the patients treated so far we saw stabilization or
even improvement of neurological status in 15 out of 16
patients. The hospital stay for every neoadjuvant therapeutic
cycle is currently two days and has the potential to become
an ambulatory procedure. Concerning toxicity, we mainly
have to face the side effects of steroid medication during
neoadjuvant treatment. In the patients treated by the
abbreviated amended protocol, we did not observe signifi-
cant weight gain or the development of Cushing’s stigmata.
Conclusion
Neoadjuvant therapy is a well established oncological
strategy in several types of cancer. As an innovative ther-
apeutic strategy in neuro-oncology, neoadjuvant local
treatment of malignant gliomas using the peptidic vector
[90Y]-DOTAGA–substance P could be shown to be fea-
sible. By achieving a high extent of resection and addi-
tional targeting of tumor cells in the infiltration zone, this
method carries the potential to prolong the time to recur-
rence and to improve the overall outcome in respect of
survival times and quality of life.
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